Malignant islet cell tumor, a rare type of neuroendocrine carcinoma, biologically behaves in an aggressive way and is difficulty to be treated. Sunitinib malate, a novel tyrosine kinase inhibitor, demonstrates a high efficacy in treating malignant islet cell tumor as shown by promising results in recent trials.

In the past decade, liquid chromatography-mass spectrometry has undergone rapid development in clinical laboratory medicine.Benefiting from the high sensitivity and specificity, as well as the capability of multi-component analysis in the single run, such technology is regarded as an excellent alternative to conventional immunoassays towards newborn screening for the genetic diseases, therapeutic drug monitoring and endocrine hormones detection.With the continuing progress in expertise-training, quality assurance and methodology standardization, it could be expected that liquid chromatography-mass spectrometry would become a dynamic and crucial part for routine clinical applications in the near future.

The intramedullary expand self-locking nail(IESN) is a new type of solid small diameter nail consisting of the dynamic and the static types, designed on the basis of the CAIN. The mechanical experiments showed that its stiffness to resist the bending and twisting momentum was simillar to the Russell -Taylor's nail. The static nail was stable enough to prevent axial displacements of the fractured segments. The main characteristics of the IESN are as follows: 1) It is being able to be inserted without reaming the medullary cavity and without X- ray guidance; 2) a higher limit value to resist fatique and 3) no stress concentration on IESN.

Objective To investigate the effect of myeloid differentiation factor 88 inhibitor ST2825 on the autophagy of THP?1 cells infected by re?combinant mycobacterium smegmatis. Methods The myeloid differentiation factor 88 inhibitor ST2825 was applied on the THP?1 cells infected by recombinant mycobacterium smegmatis,and three groups were defined:the test group with ST2825 treatment,the control group without ST2825 treatment,and the blank group. Autophagosomes were observed under the fluorescence microscope,and the mRNA expression of Beclin?1 gene and Bcl?2gene was analyzed by RT?PCR. Results Compared with the control group,the number of autophagy fluorescent dots in the test group was ob?viously reduced(P<0. 05),and the expression levels of Beclin 1 gene and Bcl?2 gene were declined as indicated by the RT?PCR detection. Con?clusion The myeloid differentiation factor 88 inhibitor ST2825 might inhibit the autophagy of THP?1 cells through interfering the separation of Be?clin?1 and Bcl?2.

Objective:To study the effect of membrane-coating on dissolution and stability of sirolimus ( SRL) dropping pills to prove the effect and rationality of the coating process. Methods:Opadry was used as the coating material for SRL dropping pills. Com-pared with those of uncoated SRL dropping pills, the dissolution and stability of membrane-coating SRL dropping pills were studied in vitro. Results:Compared with that of uncoated SRL dropping pills, the drug release amount of membrane-coating SRL dropping pills was lower (P<0. 05), however, the stable release rate showed no significant difference (P>0. 05). After the membrane-coating, the stability of SRL dropping pills was notable enhanced under high humidity (75% ± 5%) and strong light (4500lx ± 500lx) conditions, however, the stability showed no improved under high temperature(40℃ ± 2℃) condition. Conclusion: The membrane-coating can enhance the stability of SRL dropping pills without significant effect on drug release in vitro.

Objective:To study the relative bioavailability of sirolimus ( SRL) dropping pills in rats. Methods:PEG6000 as the base, SRL dropping pills were prepared using solvent-melting method. The SRL marketed tablets as the reference preparation and rats as the animals, the relative bioavailability of SRL dropping pills was studied to obtain the pharmaceutical parameters and bioequiavail-ability. Results:Compared with that of the reference preparation, tmax of SRL dropping pills was the same (1 h). There was no signifi-cant difference in Cmax between the dropping pills and the tablets (P>0. 05). AUC0-24 of the dropping pills was notably higher than that of the marketed tablets (P<0. 05) with the bioequiavailability of 121. 98%. Conclusion:SRL dropping pills with promising bioavail-ability are valuable to be studied further.

Objective:To prepare sirolimus ( SRL) dropping pills to improve SRL solubility and dissolution. Methods:The base of SRL dropping pills was screened. The optimal formula and preparation process were also optimized by orthogonal design. The equi-librium solubility, hygroscopicity and drug release in vitro of SRL dropping pills were studied. Results: PEG6000 was chosen as the base. The optimal preparation conditions of SRL dropping pills were as follows: the ratio of SRL and base was 1∶10, the dropping speed was 65 drops/min, the dropping temperature was 95℃ and the temperature of cooling solvent was 5℃. The equilibrium solubili-ty of SRL dropping pills in different solvents was increased significantly compared with that of SRL. The hygroscopicity of the dropping pills was notable. The drug release in vitro of SRL dropping pills was similar to that of the marketed tablets with quick and complete re-lease. Conclusion:SRL dropping pills exhibit increased solubility and improved dissolution, which are valuable to be studied further.

Objective:To coat sirolimus ( SRL) dropping pills with a membrane to enhance the ability of moisture proof. Meth-ods:Opadry was chosen as the coating material. The solvent, concentration and weight gain of the coating membrane were defined, and the coating parameters were screened. The critical relative humidity ( CRH%) of membrane-coating SRL dropping pills was detec-ted and compared with that of SRL dropping pills without coating. Results: The formula and coating parameters of membrane-coating SRL dropping pills were as follows:95% ethanol was used as the solvent, Opadry concentration was 6. 5%, the weigh gain was 4%, the inlet air temperature was (35 ± 2)℃, the inlet fluid rate was 12 ml·min-1 and the spraying pressure was 3. 0 MPa. The CRH%of memebrane-coating SRLs dropping pills was 63. 1%, which was much higher than that of uncoated SRL dropping pills (36. 1%). Conclusion:The membrane-coating can enhance the moisture proof of SRL dropping pills, which is beneficial to the stability.

Objective To investigate the serum asymmetric dimethylarginine (ADMA)expression in patients with acute cerebral infarction. Methods A total of 100 patients with acute cerebral infarction admitted to the Department of Neurology,the First Affiliated Hospital of Xi′an Medical College from March 2013 to August 2015 were enrolled retrospectively. According to the National Institutes of Health Stroke Scale (NIHSS)scores,they were divided into three groups:mild infarction (n =21;<4),moderate infarction (n =49;4 -15),and severe cerebral infarction (n = 30;> 15);100 healthy subjects without cerebrovascular disease in the same period were used as a control group. Enzyme linked immunosorbent assay was used to detect the plasma ADMA concentration,and the levels of plasma ADMA among the groups were compared. Results The concentrations of plasma ADMA of the mild,moderate,severe cerebral infarction,and the control groups were 0. 80 ± 0. 16,1. 14 ± 0. 28,1. 33 ± 0. 33,and 0. 52 ± 0. 16 μmol/ L,respectively. There were significant differences among the groups (F = 2. 32,P < 0. 05). Multivariate logistic regression analysis suggested that ADMA was an independent risk factor for cerebral infarction (OR,1. 140,95% CI 1. 078 -1. 212,P = 0. 045). Conclusions The expression levels of plasma ADMA increased gradually in patients with mild,moderate,and severe cerebral infarction. The higher the ADMA levels,the severe the neurological deficit would be. ADMA might be an independent risk factor for cerebral infarction.

Objective To analyze the difference between primary biliary cirrhosis (PBC) and primary Sj(o)gren's syndrome (pSS) and primary biliary cirrhosis complicating with Sj(o)gren's syndrome (SS) in clinical features,anti-60 000 SSA multiple antigenic peptides (MAPs) detection rate,and explore the potential mechanisms of PBC with SS.Methods MAPs were artificially synthesized.Enzyme-linked immunosorbent assay (ELISA) was done to detect anti-MAPs antibodies in the sera of the three groups of patients.The detection rates of anti-MAPs antibodies were compared among groups and the relations of anti-MAPs antibodies with clinical features were analyzed.Chi-square test,Fisher's exact test,t test or Wilcoxon signed rank test were conducted in this study.Results There was no significant difference in clinical features,liver function tests and antibody profiles between PBC and PBC with SS.Significant difference of anti-MAP20 antibody detection rote was detected between pSS and PBC with SS groups [25％(7/28) vs 0(0/25),x2=7.201 1,P=0.007 3],and anti-MAP3,7 and 17 antibody detection rates in PBC with SS patients [4％(1/25),4％(1/25),8％(2/25)] were similar to pSS [4％(1/28),7％(2/28),7％(2/28)].The anti-MAP7 antibody and anti-MAP12 antibody detection rates were significantly higher in patients with splenomegaly than patients without splenomegaly [38％(3/8) vs 2％(2/84),38％(3/8) vs 4％(3/84); P=0.039 4,P=0.039 4],while the antiMAP17 antibody detection rate was significantly lower in patients with salivary gland injury than patients without salivary gland injury [5％(3/64) vs 39％(5/13); x2=4.431 8,P=0.035 3].Conclusion There is significant difference in the anti-MAPs detection rates among the three patients groups,and the detection rate may be higher in patients with certain clinical manifestations.